

Endonovo Therapeutics, Inc. (OTCQB: ENDV)
 6320 Canoga Ave
 15th Floor
 Woodland Hills, CA 91367

Share Price	\$0.05
Volume	3,31m
Shares Outstanding	366,118,767
Market Cap	\$17.57m
52 Week High	\$0.09
52 Week Low	\$0.02

as of 10/15/2018



Overview

Endonovo Therapeutics, Inc. (OTCQB: ENDV) is a biotechnology company developing off-the-shelf regenerative products that no longer require the injection of stem cells. Our first platform, Cell Free Therapeutics, harnesses the biological secretions of cells to create therapies that can be immediately administered following injuries or to treat acute and chronic diseases. Our second platform is the development of non-invasive, bioelectronics to stimulate the body's natural repair system to treat injuries and inflammatory diseases.

Disclaimer

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The Company does not undertake any obligation to update forward-looking statements. All trademarks and brand names are the property of their respective companies.

Management Team

- Alan Collier**
Chairman & Chief Executive Officer
- Michael Mann**
President
- Leonard Makowka, M.D., Ph.D.**
Chief Medical Officer
- Don Calabria**
Chief Operating Officer

Recent News

- Tuesday, August 14, 2018 - 09:25 AM
[Endonovo Therapeutics Signs Distribution Agreement For National Distribution of Sofpulse® Electroceutical™ System](#)
- Thursday, June 14, 2018 - 08:30 AM
[Endonovo Therapeutics Announces Enrollment of First Patient in Clinical Study at the University of New Mexico for Treating Traumatic Brain Injury Using Its Electroceutical™ Therapy](#)
- Wednesday, May 09, 2018 - 01:30 PM
[Endonovo Therapeutics Signs Distribution Agreement with Plagens Medical Consultants for its Pain Relief Electroceutical™ SofPulse®](#)
- Tuesday, May 01, 2018 - 07:35 AM
[Endonovo Therapeutics Highlights Feasibility Study Results of Its Electroceutical Therapy in Reducing Proteinuria in Chronic Kidney Disease Patients](#)
- Wednesday, April 18, 2018 - 10:00 AM
[Endonovo Therapeutics Inc. to Move Forward with a Clinical Research Study Conducted by the Regents of the University of New Mexico](#)